Tarextumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | Notch 2, Notch 3 |
Clinical data | |
Legal status |
|
ChemSpider | none |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In Jan 2015 the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]
See also
- Notch signaling pathway, e.g. in embryo tissue development
References
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.